Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 18/20 | 0.80 |
| ▸ | ABHD6 | Q9BV23 | 12/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | PLA2G7 | Q13093 | 7/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18064838 | 0.94 | MGLL (0.82) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL18064780 | 0.93 | MGLL (0.78) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL19992949 | 0.91 | MGLL (0.80) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL18064918 | 0.91 | MGLL (0.81) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL19992934 | 0.91 | MGLL (0.79) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL19992767 | 0.90 | MGLL (0.71) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL18064875 | 0.90 | MGLL (0.74) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL19992768 | 0.90 | MGLL (0.76) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL18064910 | 0.90 | MGLL (0.79) | MGLLABHD6CYP2D6PLA2G7 | |
| SCHEMBL22273329 | 0.90 | MGLL (0.79) | MGLLABHD6CYP2D6PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| CN-107660199-B | Piperazine carbamates and methods of making and using the same | H.隆德贝克有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| EP-3271352-B1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020154683-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994537-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-3271352-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-23 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771341-B2 | Piperazine carbamates and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| WO-2016149401-A2 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272602-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | MGLL 46/4885ABHD6 1/4885CYP2D6 386/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | MGLL 1/4885ABHD6 49/4885CYP2D6 4514/4885 |
| US-20170334874-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | MGLL 46/4885ABHD6 1/4885CYP2D6 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.